CLDN18 and intrahepatic cholangiocarcinoma: Crucially, combined CLDN18.2/CD8+ T-cell stratification identified distinct prognostic subgroups, CLDN18.2+/CD8low ICC patients had the worst prognosis (P = 0.006).